De-alcoholization of paclitaxel injection for clinical application

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4339-4346

  Tsukiyama, Ikuto ^a,b   Takeuchi, Masayuki ^a   Abe, Fumie ^c   Kisi, Takahiko ^a   Saito, Hiroko ^a   Obayashi, Yukihiko ^a   Watanabe, Kazushi ^a   Wakatsuki, Akihiko ^a   Miyamoto, Ken Ichi ^b   Hasegawa, Takaaki ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Adverse event; Alcohol intolerance; De alcoholization; Paclitaxel (PTX); Pharmacokinetics

Indexed keywords

ALCOHOL; CARBOPLATIN; PACLITAXEL;

AGED; ALCOHOL INTOLERANCE; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACTERIUM CONTAMINATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DEALCOHOLIZATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; DRUG TRANSFORMATION; FATIGUE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOT FLUSH; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKOPENIA; LIQUID CHROMATOGRAPHY; MALE; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; RAT; SALPINGOOOPHORECTOMY; SOMNOLENCE; TANDEM MASS SPECTROMETRY; THROMBOCYTOPENIA; UTERUS CANCER; VISCOSITY; VOMITING;

ALCOHOLS; ANIMALS; BACTERIA; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; EQUIPMENT DESIGN; ETHANOL; HUMANS; MALE; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VISCOSITY;

EID: 84855166024     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Sagara Y, Rai Y, Sagara Y, Matsuyama Y, Baba S, Tamada S, Sagara Y and Ando M: Comparison of the pharmacokinetics and safety of a paclitaxel injection NK and Taxol® injection in breast cancer patients. Jpn J Cancer Chemother 36: 247-250, 2009 (in Japanese).
2. Tarr BD and Yalkowsky SH: A new parenteral vehicle for the administration of some poorly water soluble anticancer drugs. J Parenter Sci Technol 41: 31-33, 1987. (Pubitemid 17034075)
3. Swindell CS, Krauss NE, Horwitz SB and Ringel I: Biologically active taxol analogues with deleted A-ring side chain substituents and variable C-2′ configurations. J Med Chem 34: 1176-1184, 1991.
4. Ringel I and Horwitz SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288-291, 1991.
5. Mathew AE, Mejillano MR, Nath JP, Himes RH and Stella VJ: Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. J Med Chem 35: 145-151, 1992.
6. Penton Z: Headspace measurement of ethanol in blood by gas chromatography with a modified autosampler. Clin Chem 31: 439-441, 1985.
7. Zhao M, Rudek MA, Mnasakanyan A, Hartke C, Pili R and Baker SD: A liquid chromatography/tandem mass spectrometry assay to quantitate MS human plasma. J Pharm Biomed Anal 43: 784-787, 2007. (Pubitemid 44960582)
8. National Institute of Health Science, Japan. Guideline for Bioequivalence Studies of Generic Products. http://www.nihs.go.jp/drug/be-guide(e)/Generic/ be97E.pdf (accessed May 1st 2009).
9. Drug interview form of Paclitaxel NK. Tokyo, Japan: Nippon Kayaku Co. Ltd; 2011 May (in Japanese). http://mink.nipponkayaku.co.jp/common/in-file/sedi- paci-in.pdf (accessed May 1st 2009).
10. Goda R, Yamaguchi T, Yamashita T, Yazawa Y, Kawashiro T, Arai S, Wakizaka Y and Nakamura M: Plasma concentration in dogs, compatibility and drip rate of Paclitaxel inj. 30 mg/5 ml NK. Jpn J Med Pharmaceut Sci 56: 563-570, 2006 (in Japanese).
11. Rai Y, Arai S, Ohata H, Sagara Y and Sagara Y: Comparative study of compatibility and quality between Paclitaxel injection 100 mg/16.7 ml NK and Taxol® injection 100 mg/16.7 ml. Jpn J Med Pharm Sci 57: 319-324, 2007 (in Japanese).
12. Kobo B: Transfusion line for Taxol inj. Third report - polyvinylchloride (PVC) transfusion set plasticized by TOTM [tris(2-ethylhexyl)trimellitate] and drop count per 1 ml. J New Remedies Clinics 52: 126-134, 2003 (in Japanese).
13. Tamura T, Sasaki Y, Nishiwaki Y and Saijo N: Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res 86: 1203-1209, 1995.
14. Omura T, Fujisawa H, Muro C, Yamashita N, Kuroda N, Hamaguchi T and Kadobayashi M: Factors affecting infusion rate of paclitaxel injection solution when using infusion pumps. Jpn J Pharm Health Care Sci 34: 467-473, 2008 (in Japanese).
15. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N and Hortobagyi GN: Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23: 6019-6026, 2005.
16. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M and O'Shaughnessy J: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23: 7794-7803, 2005. (Pubitemid 46657376)